Literature DB >> 16551668

Lithium in maintenance therapy for bipolar disorder.

Allan H Young1, James I Newham.   

Abstract

Lithium has been used for the medical treatment of bipolar disorder for over 50 years. The purpose of this paper is to review the evidence base supporting the use of lithium in the maintenance phase of treatment of bipolar disorder and the limitations which reduce the clinical effectiveness of this medication. A selective review of the relevant literature was carried out. It is concluded that lithium is efficacious in the maintenance phase treatment of bipolar disorder, with the available evidence supporting a beneficial effect which prevents recurrence of mania; it is less clear if lithium prevents depressive episodes in bipolar disorder. A number of lines of evidence support the notion that lithium reduces suicidal acts and completed suicide. Lithium has a significant side effect burden and a narrow therapeutic index. It is also associated with an increased liability for new episodes, both manic and depressive, consequent upon stoppage of treatment. These factors limit the clinical effectiveness of lithium.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16551668     DOI: 10.1177/1359786806063072

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  11 in total

1.  The incidence and clinical correlates of lithium toxicity: a retrospective review.

Authors:  U Dennison; M Clarkson; J O'Mullane; E M Cassidy
Journal:  Ir J Med Sci       Date:  2011-04-23       Impact factor: 1.568

2.  Trends in laboratory test volumes for Medicare Part B reimbursements, 2000-2010.

Authors:  Shahram Shahangian; Todd D Alspach; J Rex Astles; Ajay Yesupriya; William K Dettwyler
Journal:  Arch Pathol Lab Med       Date:  2013-06-05       Impact factor: 5.534

3.  Cost effectiveness of a pharmacist-led information technology intervention for reducing rates of clinically important errors in medicines management in general practices (PINCER).

Authors:  Rachel A Elliott; Koen D Putman; Matthew Franklin; Lieven Annemans; Nick Verhaeghe; Martin Eden; Jasdeep Hayre; Sarah Rodgers; Aziz Sheikh; Anthony J Avery
Journal:  Pharmacoeconomics       Date:  2014-06       Impact factor: 4.981

4.  The diagnosis and treatment of bipolar disorder: decision-making in primary care.

Authors:  Larry Culpepper
Journal:  Prim Care Companion CNS Disord       Date:  2014-06-19

5.  Lithium activates brain phospholipase A2 and improves memory in rats: implications for Alzheimer's disease.

Authors:  Fábio B Mury; Weber C da Silva; Nádia R Barbosa; Camila T Mendes; Juliana S Bonini; Jorge Eduardo Souza Sarkis; Martin Cammarota; Ivan Izquierdo; Wagner F Gattaz; Emmanuel Dias-Neto
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-12-11       Impact factor: 5.270

6.  Neuroprotective Effects of Açaí (Euterpe oleracea Mart.) against Rotenone In Vitro Exposure.

Authors:  Alencar Kolinski Machado; Ana Cristina Andreazza; Tatiane Morgana da Silva; Aline Augusti Boligon; Vanusa do Nascimento; Gustavo Scola; Angela Duong; Francine Carla Cadoná; Euler Esteves Ribeiro; Ivana Beatrice Mânica da Cruz
Journal:  Oxid Med Cell Longev       Date:  2016-10-03       Impact factor: 6.543

Review 7.  Bipolar patients and creative online practices: Sharing experiences of controversial treatments.

Authors:  Claudia Egher
Journal:  Health (London)       Date:  2019-03-28

8.  TRPM2, a Susceptibility Gene for Bipolar Disorder, Regulates Glycogen Synthase Kinase-3 Activity in the Brain.

Authors:  Yongwoo Jang; Sung Hoon Lee; Byeongjun Lee; Seungmoon Jung; Arshi Khalid; Kunitoshi Uchida; Makoto Tominaga; Daejong Jeon; Uhtaek Oh
Journal:  J Neurosci       Date:  2015-08-26       Impact factor: 6.167

9.  Neuronal apoptosis and motor deficits in mice with genetic inhibition of GSK-3 are Fas-dependent.

Authors:  Raquel Gómez-Sintes; José J Lucas
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

10.  Lithium chloride effectively kills the honey bee parasite Varroa destructor by a systemic mode of action.

Authors:  Bettina Ziegelmann; Elisabeth Abele; Stefan Hannus; Michaela Beitzinger; Stefan Berg; Peter Rosenkranz
Journal:  Sci Rep       Date:  2018-01-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.